CytoDyn Inc, a clinical-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies for the treatment and prevention of human immunodeficiency virus (HIV) infection. Its lead product is PRO 140, a therapeutic anti-viral agent, which is in Phase IIb treatment substitution trial, Phase IIb extension study, Phase IIb/III pivotal trial, and Phase IIb/III investigative trial for HIV; and Phase II trial for graft-versus-host disease.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone360-980-8524
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees6
Next Earnings Date10/22/2019 (Estimated)
OptionableNot Optionable
CytoDyn (OTCMKTS:CYDY) Frequently Asked Questions
What is CytoDyn's stock symbol?
CytoDyn trades on the OTCMKTS under the ticker symbol "CYDY."
How were CytoDyn's earnings last quarter?
CytoDyn Inc (OTCMKTS:CYDY) released its quarterly earnings data on Wednesday, August, 14th. The biotechnology company reported ($0.05) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.04) by $0.01. View CytoDyn's Earnings History.
When is CytoDyn's next earnings date?
What price target have analysts set for CYDY?
1 brokers have issued 12-month target prices for CytoDyn's stock. Their forecasts range from $1.00 to $1.00. On average, they expect CytoDyn's share price to reach $1.00 in the next year. This suggests a possible upside of 208.7% from the stock's current price. View Analyst Price Targets for CytoDyn.
What is the consensus analysts' recommendation for CytoDyn?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytoDyn in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CytoDyn.
What are Wall Street analysts saying about CytoDyn stock?
Here are some recent quotes from research analysts about CytoDyn stock:
- 1. According to Zacks Investment Research, "CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV infection. The Company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has completed Phase 2 clinical trials with demonstrated antiviral activity in humans and is currently in Phase 3 development. PRO 140 blocks the HIV co-receptor CCR5 on T cells, which prevents viral entry. Clinical trial results thus far indicate that PRO 140 does not negatively affect the normal immune functions that are mediated by CCR5. Results from seven Phase 1 and Phase 2 human clinical trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV. A recent Phase 2b clinical trial demonstrated that PRO 140 can prevent viral escape in patients during several months of interruption from conventional drug therapy. " (9/18/2019)
- 2. HC Wainwright analysts commented, "Our 12-month price target is derived from an estimated market value of the firm at $560M. It includes a discounted cash flow-based asset value of $566M for leronlimab in the HIV indication alone, with a 15% discount rate, 2% terminal growth rate, 80% probability of success, and excluding $6M debt." (3/18/2019)
Has CytoDyn been receiving favorable news coverage?
News coverage about CYDY stock has trended neutral recently, according to InfoTrie. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. CytoDyn earned a news sentiment score of 0.2 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for CytoDyn.
Who are some of CytoDyn's key competitors?
Some companies that are related to CytoDyn include Akebia Therapeutics (AKBA), Akorn (AKRX), Achillion Pharmaceuticals (ACHN), TG Therapeutics (TGTX), Basilea Pharmaceutica (BPMUF), Retrophin (RTRX), Myovant Sciences (MYOV), Viking Therapeutics (VKTX), INDIVIOR PLC/S (INVVY), Aptorum Group (APM), Urogen Pharma (URGN), Sinovac Biotech (SVA), Intra-Cellular Therapies (ITCI), Lannett (LCI) and ChemoCentryx (CCXI).
What other stocks do shareholders of CytoDyn own?
Who are CytoDyn's key executives?
CytoDyn's management team includes the folowing people:
- Dr. Nader Z. Pourhassan, CEO, Pres & Director (Age 56)
- Mr. Michael D. Mulholland, CFO, Treasurer & Corp. Sec. (Age 67)
- Dr. Denis R. Burger, Scientific Consultant (Age 75)
- Dr. Richard G. Pestell M.B.A., M.D., MBA. M.D., Ph.D., Vice Chairman & Chief Medical Officer
- Dr. Nitya G. Ray, Chief Technology Officer & Head of Process Sciences, Manufacturing and Supply Chain (Age 66)
How do I buy shares of CytoDyn?
Shares of CYDY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is CytoDyn's stock price today?
One share of CYDY stock can currently be purchased for approximately $0.32.
How big of a company is CytoDyn?
CytoDyn has a market capitalization of $125.58 million. The biotechnology company earns $-56,190,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. CytoDyn employs 6 workers across the globe.View Additional Information About CytoDyn.
What is CytoDyn's official website?
How can I contact CytoDyn?
CytoDyn's mailing address is 1111 MAIN STREET SUITE 660, VANCOUVER WA, 98660. The biotechnology company can be reached via phone at 360-980-8524 or via email at [email protected]
MarketBeat Community Rating for CytoDyn (OTCMKTS CYDY)
MarketBeat's community ratings are surveys of what our community members think about CytoDyn and other stocks. Vote "Outperform" if you believe CYDY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYDY will underperform the S&P 500 over the long term. You may vote once every thirty days.
